Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian T Chan

Showing results (31-40 of 32) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 32 results.
New Microbes and New Infections|September 2, 2025
An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunityIsabel H Gonzalez-Bocco, Rayven Frierson, Alyssa Cho, et al.
The New England Journal of Medicine|November 11, 2020
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised HostBina Choi, Manish C Choudhary, James Regan, et al.
Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 32 results.
New Microbes and New Infections|September 2, 2025
An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunityIsabel H Gonzalez-Bocco, Rayven Frierson, Alyssa Cho, et al.
The New England Journal of Medicine|November 11, 2020
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised HostBina Choi, Manish C Choudhary, James Regan, et al.
Pageof 4